ArticleRenal failure2023
Clinical significance of serum glucose to lymphocyte ratio as a prognostic marker in peritoneal dialysis patients.
Article in Renal failure, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Association of the glucose-to-lymphocyte ratio with all-cause and cardiovascular disease mortality in U.S. adults: A population-based cohort study.Clinics (Sao Paulo, Brazil) · 2026Article
- Prognostic value of glucose-to-lymphocyte ratio for all-cause mortality and consciousness impairment in critically ill cerebrovascular disease patients.European journal of medical research · 2025Article
- Inflammatory Markers and Saphenous Vein Graft Stenosis: Insights into the Use of Glucose-to-Lymphocyte Ratio as a Prognostic Marker.Journal of clinical medicine · 2025Article
- The Glucose-to-Lymphocyte Ratio Predicts All-cause Mortality and Cardiovascular Mortality in ST-Elevation Myocardial Infarction Patients: A Retrospective Study.Reviews in cardiovascular medicine · 2025Article
- Relationship between glucose to lymphocyte ratio and the first peritonitis episode in patients treated with peritoneal dialysis.Scientific reports · 2025Article
- Inflammation, glucose metabolism, and nutritional markers in relation to all-cause and cardiac mortality among initial hemodialysis patients: a multicenter cohort study.Frontiers in nutrition · 2025Article
- The Role of Glucose-Lymphocyte Ratio in Evaluating the Severity of Coronary Artery Disease.Journal of clinical medicine · 2024Article
- Platelet-to-albumin ratio: a potential biomarker for predicting all-cause and cardiovascular mortality in patients undergoing peritoneal dialysis.BMC nephrology · 2024Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe glucose-to-lymphocyte ratio (GLR), a glucose metabolism and systemic inflammatory response parameter, is associated with an adverse prognosis for various diseases. However, the association between serum GLR and prognosis in patients undergoing peritoneal dialysis (PD) is poorly understood.
methodsIn this multi-center cohort study, 3236 PD patients were consecutively enrolled between 1 January 2009 and 31 December 2018. Patients were divided into four groups according to the quartiles of baseline GLR levels (Q1: GLR ≤ 2.91, Q2:2.91 < GLR ≤ 3.91, Q3:3.91 < GLR < 5.59 and Q4: GLR ≥ 5.59). The primary endpoint was all-cause and cardiovascular disease (CVD) related mortality. The correlation between GLR and mortality was examined using Kaplan-Meier and multivariable Cox proportional analyses.
resultsDuring the follow-up period of 45.93 ± 29.01 months, 25.53% (826/3236) patients died, of whom 31% (254/826) were in Q4 (GLR ≥ 5.59). Multivariable analysis revealed that GLR was significantly associated with all-cause mortality (adjusted HR 1.02; CI 1.00 ∼ 1.04,
conclusionA higher serum GLR level is an independent prognostic factor for all-cause and CVD mortality in patients undergoing PD, suggesting that more attention should be paid to GLR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.